Agenus (NASDAQ:AGEN) issued its earnings results on Thursday. The biotechnology company reported $0.12 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.30) by $0.42, Fidelity Earnings reports. The firm had revenue of $8.61 million for the quarter, compared to analysts’ expectations of $9.03 million.
NASDAQ AGEN traded down $0.02 on Friday, reaching $2.86. The company had a trading volume of 77,495 shares, compared to its average volume of 1,446,751. The stock has a market cap of $401.43 million, a PE ratio of -1.98 and a beta of 1.96. Agenus has a 1 year low of $1.54 and a 1 year high of $3.88.
A number of research firms have weighed in on AGEN. BidaskClub upgraded Agenus from a “strong sell” rating to a “sell” rating in a report on Tuesday. ValuEngine upgraded Agenus from a “hold” rating to a “buy” rating in a report on Thursday, January 17th. Zacks Investment Research upgraded Agenus from a “sell” rating to a “hold” rating in a report on Thursday, January 24th. Finally, B. Riley began coverage on Agenus in a report on Monday, April 22nd. They issued a “buy” rating and a $5.00 price target for the company.
Agenus Company Profile
Agenus Inc, a clinical-stage immuno-oncology company, focuses on the discovery and development of therapies that engage the body's immune system to fight cancer. The company offers Retrocyte Display, an antibody discovery platform for the identification of fully-human and humanized monoclonal antibodies; SECANT yeast display, an antibody discovery platform used for the generation of novel monoclonal antibodies; and phage display technologies.
Further Reading: P/E Growth (PEG)
Receive News & Ratings for Agenus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agenus and related companies with MarketBeat.com's FREE daily email newsletter.